Background. Human immunodeficiency virus (HIV)-infected individuals are at increased risk of invasive pneumococcal disease (IPD). In order to assess the immunogenicity of pneumococcal proteins and polysaccharide, we investigated protein and serotype-specific antibody responses after HIV-associated IPD.
Infection with human immunodeficiency virus (HIV) is associated with an increased risk of invasive pneumococcal disease (IPD). Rates may be as much as 100-fold higher for untreated individuals, and with antiretroviral treatment (ART) rates are 20-50 times higher compared to HIV-uninfected individuals [1] [2] [3] [4] [5] [6] . Recurrence of IPD is frequent with HIV infection [7] . Defective T-cellmediated immunity strongly predisposes for IPD [7, 8] and defective B-cell-mediated immunity following HIV infection may also play a role in susceptibility [9, 10] . In HIV-infected individuals, impaired and altered immunoglobulin function and responses to Streptococcus pneumoniae have been demonstrated [11] [12] [13] [14] . In a study performed prior to the introduction of ART, less than half of individuals with IPD had measurable killing activity against S. pneumoniae in convalescent serum [11] .
Most guidelines recommend vaccination with the 23valent pneumococcal polysaccharide vaccine (PPV23) for protection against IPD [15] , although several reports have questioned PPV23's effectiveness in reducing pneumococcal disease among HIV-infected individuals [16, 17] . The 7-valent conjugated pneumococcal vaccine (PCV7) has been shown to prevent recurrent IPD but has not been studied as a primary intervention in a controlled trial [7] . The 13-valent conjugated pneumococcal vaccine (PCV13) has lately also been recommended for high-risk groups [18] . Both the pneumococcal polysaccharide vaccine (PPV) and pneumococcal conjugate vaccine (PCV) have restricted protection because they only protect against the serotypes included in the vaccine.
Specific antibodies against pneumococcal protein are formed during colonization, and in experimental challenge models of colonization in humans, the preexistence of protein-specific antibodies protects against colonization [19, 20] . Pneumococcal proteins are obvious candidates for a broadly protective protein-based antipneumococcal vaccine.
Natural infection with S. pneumoniae provides an opportunity to simultaneously gauge the response to a large number of pneumococcal antigens. Thus, to study the immunogenicity of pneumococcal proteins following infection and thereby identify likely vaccine candidates, we investigated the specific antipneumococcal protein and polysaccharide antibody responses to IPD.
METHODS

Study Population
IPD Samples
We conducted a matched case-control study of HIV-1-infected individuals who attended the Department of Infectious Diseases, Hvidovre Hospital, and had an incidence of IPD from February 1987 through May 2010. Cases were identified by merging the database of the national surveillance data on IPD (National Neisseria and Streptococcus Reference Centre, Statens Serum Institut, Copenhagen, Denmark) with the repository database of stored samples maintained at Hvidovre Hospital. Eligible for the study were individuals with culture-confirmed IPD and stored serum or plasma samples pre-and post-IPD. Samples collected at each visit were stored at −80°C. HIV-1-infected individuals without IPD served as controls and were matched on age and sex. Samples for the controls were collected at HIV patient's routine visit at the hospital.
Demographic information (age, ethnicity, and transmission group) and HIV parameters ( plasma HIV RNA, blood CD4 T-cell count, AIDS, and ART) were extracted from patient files.
IPD serotypes were obtained from the National Neisseria and Streptococcus Reference Centre. Isolates were routinely serotyped by pneumotest latex and the Quellung reaction using type-specific pneumococcal rabbit antisera from SSI Diagnostica (Hillerød, Denmark) as previously described [21, 22] .
The study was approved by the Danish Data Protection Agency (record no. 2012-41-1068).
Protein-Specific Antibody Measurement
A direct binding electrochemiluminescence-based multiplex assay were used to measure serum or plasma immunoglobulin G (IgG) antibodies to 27 pneumococcal protein antigens and performed at the Institute of Child Health, University College London, London, United Kingdom. The assay was based on that described for pneumococcal polysaccharide antigens utilizing MesoScale Discovery (MSD, Rockville, Maryland) technology [23] and coated at a concentration of 25 µg/mL. For each plate, pneumococcal reference serum 007sp was used as a standard and assigned a value of 1000 arbitrary units for each antigen [24] . Antibody levels in plasma or serum samples from study participants were expressed as a titer with reference to the amount in 007sp.
The upper limit of detection was assigned to samples with antibody concentrations above the range of the standard curve. Of 8523 results, 3 were assigned the upper limit of detection (see Supplementary data for informations on proteins).
Protein Functionality
Proteins were classified into 10 groups according to their function. Choline-binding proteins (CBPs): CbpA, LytA, LytC, and PcpA [25] ; LPXTG (L = leucine, P = proline, X = any amino acid, T = threonine, G = glycine)-anchored proteins: NanA, StkP, and StrH [25, 26] (http://www.uniprot.org/); cysteine histidine-dependent amidohydrolase/peptidase domain (CHAD): PcsB-1 and PcsB-2 [27] ; poly-histidine triad (PHT): PhtD-1, PhtD-2, and PhtE [25] ; adenosine triphosphate (ATP)-binding cassette (ABC) transporter: PiaA, PiuA, PsaA, PspA-Fam1, PspA-Fam2, and SP0609 [25] ; toxin: Ply-1 and Ply-2 [25] ; collagen-binding surface protein (CBSP): RrgA-T4, RrgB-T4, RrgB-6B, and RrgB-23F (http://www.uniprot.org/); ATPase: SP2194 [28] ; LysM domain: Spr0096 [27] and unknown: SP2027.
The pneumococcal proteins are well conserved or, where there are 2 or more dominant clades, all clades are represented in the array.
Serotype-Specific Antibody Measurement
PCV Serotypes
Antibody measurement of specific antipneumococcal IgG to serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all included in the 13-valent PCV, were done with a Luminex-based assay described in detail elsewhere [29, 30] and performed at Statens Serum Institut. Pneumococcal polysaccharide serum calibrated to FDA 89SF reference serum was used as reference [31] . Antibody levels were expressed as µg/mL. Specific antigens were purchased from LGC Standards (American Type Culture Collection, Manassas, Virginia).
Serotype 6A specific antipneumococcal IgG antibodies were measured as described below for non-PCV serotypes.
Non-PCV Serotypes
Antibody measurement of specific antipneumococcal IgG antibodies to serotypes 6A, 8, 9N, 10A, 10F, 11A, 12F, 13, 15A, 17F, 20, 24F, 31, 33F, 35F, 38, and 48 was done using a Luminexbased assay. Briefly, pneumococcal lipopolysaccharides, kindly supplied by SSI Diagnostica, were conjugated to poly-L-lysine (PLL), and these complexes were then conjugated to carboxylated microspheres (Luminex, Austin, Texas). Polysaccharides were reconstituted in DNase/RNase-free water to 3.33 mg/mL. The antibody level was measured in mean fluorescence intensity (MFI).
Statistics
All values are expressed as mean and standard deviation. Differences in continuous variables were tested using the Mann-Whitney test and differences in proportions using χ 2 statistics or the Welch 2-sample t-test. A 2-fold or greater rise in antibody concentration from pre-to post-IPD was used to define a "response." Response was evaluated for 27 proteins, the specific disease causing polysaccharide IPD type for each IPD case, and an additional 12 polysaccharides (PCV types) for non-IPD cases.
The optimal protein response threshold between IPD and non-IPD were calculated with receiver operating characteristic (ROC), where non-IPD was defined as the "healthy" group.
Associations between antibody responses ( protein, protein group, or polysaccharide) among IPD cases and between cases and controls were estimated by logistic regression analysis with and without adjustment for age, CD4 T-cell count, ART, and HIV transmission group, and reported as an odds ratio (OR) with 95% confidence interval (95% CI). Antibody profiles over time were evaluated by linear regression.
We used the method of Bonferroni to control for multiple comparisons. Each subject had 28 comparisons (27 proteins and 1 polysaccharide). Significance was set at P < .0017.
All calculations were done using SPSS 18 for Windows or R 2.15.2 for Windows.
RESULTS
Subject Characteristics
Forty-nine cases of HIV-associated IPD and 39 non-IPD controls were identified. The 2 groups were comparable with regard to age and HIV-transmission group, but non-IPD controls were more likely to have received ART ( 
Pneumococcal Protein Antibody Responses
Pneumococcal protein antibodies were measured in 47 IPD cases and 39 non-IPD cases. Thirty-eight of 47 IPD cases (81%) had a 2-fold increase in at least 1 antiprotein antibody pre-and post-IPD. In comparison, 20 of 39 (51%) non-IPD cases had a 2-fold increase in at least 1 antiprotein antibody between 2 samples. Overall, cases with IPD had a response to more proteins than non-IPD cases (8.6 ± 8.4 vs 4.2 ± 7.6; P = .01). For IPD cases, 38 (81%) had a response to 1 or more proteins, 31 (79%) had a response to 3 or more proteins, and 27 (57%) had a response to 5 or more proteins compared to non-IPD cases where 20 (51%) had a response to 1 or more proteins, 12 (31%) had a response to 3 or more proteins, and 10 (26%) had a response to 5 or more proteins. One IPD case (2%) and 2 non-IPD controls (5%) responded to all 27 proteins. Nine HIV IPD cases (19%) did not respond to any of the proteins. Nonresponders tended not to be on ART as compared to responders (1 of 8 vs 17 of 38; P = .07). In addition, CD4 T-cell counts were lower in nonresponders compared to responders (147 ± 167 vs 248 ± 202; P = .18).
ROC analysis showed that the optimal cut-off between IPD and non-IPD was response to 5 proteins; this gave a sensitivity of 62%, a specificity of 74%, and an area under the curve (AUC) of 0.695 (95% CI, .584-.809).
Cases with IPD were more likely to have a 2-fold increase in antibody titer before correction for multiple testing to 14 of the 27 proteins than non-IPD cases: CbpA, PcpA, PcsB-1, PcsB-2, PhtD-2, PhtE, PiaA, PiuA, Ply-2, PsaA, PspA-Fam1, PspA-Fam2, RrgB-T4, and Spr0096, and after correction, IPD cases had a significantly higher response against PiaA, PsaA, and PcpA (Table 2) . IPD cases were more likely to have a response to 7 of the 10 (70%) groups of proteins based on function than the non-IPD group ( Table 3 ). The protein groups with the highest likelihood of response for IPD cases as compared to non-IPD cases were choline-binding proteins (OR, 5.14 [95% CI, 2.48-11.38]; P = <.001) and ABC transporter (OR, 3.86 [95% CI, 2.50-6.09]; P = <.001).
Maximum antibody concentration post-IPD was reached between day 147 ± 124 (PcpA) and 188 ± 189 (RrgB-23F) post-IPD, corresponding to a mean between sample 1 and 2 post-IPD. There was no significant difference between time to maximum antibody concentration and response to above or below 5 proteins (data not shown). For IPD cases where post-IPD antibody levels returned to the pre-IPD level, cases with response to more than 5 proteins returns after a mean of 230 ± 109 days. There was no significant difference between IPD-cases with response to above or below 5 proteins (data not shown).
For IPD cases, postinfection protein antibody levels decreased for 49% of the IPD cases compared to a change over time from first to third sample for 54% of the non-IPD controls (P = NS).
Capsular Polysaccharide Antibody Responses
The serotype distribution among the 49 IPD cases was: type 4 (7/ 49: 14%), 9V (5/49: 10%), 14 and 23F (each 3/49: 6%), 6A, 8, 11A, 18C, 19F, 20, 24F, and 33F (each 2/49: 4%), 1, 3, 7F, 9N, 10A, 10F, 12F, 13, 15A, 17F, 19A, 31, 35F, 38, and 48 (each 1/49: 2%).
Eleven (22%) of 49 IPD cases had a 2-fold increase in capsular polysaccharide antibody to the infecting pneumococcal serotype. For 6 of 11 responders, antibody levels returned to pre-IPD levels after 344 ± 128 days, whereas 5 cases maintained or increased their serotype-specific antibody levels postinfection. They had a maximum disease-causing serotype antibody concentration at the first sample after IPD corresponding to 32 ± 23 days.
Of the 39 HIV-infected non-IPD controls, 32 had a polysaccharide antibody profile that either did not change or decreased over time. Of the remaining 7, 3 had serotype 23F-specific antibodies increases from the second to third sample; 4 samples had an increase in the antibody concentration between 2 samples (two serotype 1 and one of each serotype 18C and 19F). Response: Two-fold increase in antibody concentration from pre-to postinvasive pneumococcal disease for IPD cases and first to third sample for non-IPD controls.
Abbreviations: CI, confidence interval; IPD, invasive pneumococcal disease. Abbreviations: ABC, ATP-binding cassette; ATP, adenosine triphosphate; CI, confidence interval.
Predictors of an Antibody Response Among IPD Cases
Pneumococcal Protein Antibody There was no significant difference in demographic or HIV parameters among the individuals with response to 5 or more proteins as compared to less than 5 proteins. Multivariate logistic regression with response to more or equal to 1, 3, and 5 proteins and after adjustment for age, CD4 T-cell count, ART, and HIV transmission group showed no association with protein antibody response (data not shown).
Pneumococcal Polysaccharide Antibody
There was no significant difference in demographic or HIV parameters between the polysaccharide antibody responders and the nonresponders, although responders tended to be younger than nonresponders (responders: 35 ± 2.4 years vs nonresponders: 42 ± 11 years; P = .09). By multivariate logistic regression analysis after adjustment for age, CD4 T-cell count, ART, and HIV transmission group, a 1-year age increment in age was associated with a 7% decreased odds of an antibody response (OR, 0.93 [95% CI, .87-1.00]; P = .047). The remaining variables were not associated with antibody response.
DISCUSSION
We show here that the majority of HIV-1-infected individuals mount an antibody response to at least 1 pneumococcal protein, while less than a quarter mount a serotype-specific antibody response following invasive infection with S. pneumoniae. Interestingly, while serotype-specific antibody levels declined over the following year in most individuals, approximately half of protein-specific antibody levels were sustained over time. Antiretroviral treatment did not have an impact on protein-or serotype-specific antibody responses in the third of patients receiving these at the time of IPD.
IPD cases responded to a variety of pneumococcal proteins. To differentiate responses occurring after infection and colonization, respectively, we compared samples from individuals with and without IPD. Responses of non-IPD controls varied between 10% and 20%, whereas the variation in response was between 15% and 53% for IPD cases. Proteins within the ABC transporter group, particularly PiaA and PsaA, and the choline-binding proteins (PcpA) were more likely to yield an antibody response in cases compared to controls. No other study has comprehensively studied protein responses of HIV IPD cases, but several studies have investigated single-protein responses. Similarly to our study, others have shown that pneumolysin rarely induced an antibody response after IPD, suggesting that pneumolysin is a poor vaccine candidate [32] [33] [34] [35] .
Sixty-one percent of the HIV IPD cases responded to PiaA, PsaA, or PcpA. A total of 8 proteins; PsaA, Spr0096, PspA-Fam1, PspA-Fam2, 1 of (NanA or PhtD), SP0609, StkP, and 1 of (CbpA, PcsB-1 or PcsB-2) would be required in order to have a response to at least 1 pneumococcal protein. However, 9 of the IPD cases did not have measurable antibodies response to any of the pneumococcal proteins after natural infection. Our findings would suggest that a protein-based vaccine is unlikely to elicit an antibody response in a majority of HIV-infected individuals with advanced immunodeficiency, indicating that for HIV-infected individuals, it may be of benefit to delay immunization until ART is initiated or to reimmunize after ARTinduced immune restoration. Further, studies are required to determine protein composition, immunization strategy, and role of adjuvans that could improve the immunogenicity of a future protein-based vaccine. Our findings indicate that PiaA, PsaA, or PcpA combined with other proteins may be useful candidates for protein-based vaccines, assuming that antibody response is associated with subsequent protection. In support, a recent study found higher concentrations of antibody to PsaA in the acute and convalescent phase after IPD as compared to both healthy and sick controls [36] .
We found that serotype-specific antibodies declined over time in more cases than protein antibodies, though there were no significant difference between the protein antibody decline rate between HIV IPD cases and controls. However, protein antibody concentrations that declined to preinfection level did this faster than polysaccharide antibodies. Similarly, polysaccharide antibodies reached a maximum concentration faster than proteins antibodies. These results suggest that a combined protein vaccine instead of a polysaccharide vaccine could be more preventive in HIV patients.
A study of serotype-specific responses performed more than 20 years ago came to a similar result using a different methodology [11] . A serotype-specific antibody response occurred in 6 of 11 recovering individuals with HIV infection, but the response was lower than for HIV-uninfected controls. None of these individuals were treated with ART. We had expected a higher response rate in our population, given that a third of our cases were receiving ART at the time of IPD. Further, individuals receiving ART had significantly higher CD4 T-cell counts with a median count within the normal range. However, only half of the patients receiving ART had a protein response or serotype-specific antibody response compared to one-third not receiving ART. This difference was not statistically significant. Although our sample size may be too small to show a difference, an antibody response rate of 50% likely would be insufficient for a vaccine to induce protective immunity at a population level. Further, antibody levels in most responders declined over time, suggesting that natural immunity is shortlived in HIV-1-infected individuals. This phenomenon has also been seen after vaccination with PPV23 [37] . The shortlived response to PPV23 vaccination and natural infection may also in part explain the dismal results of several vaccine trials [17, 38, 39] . In particular, immunization with PPV23 has only proven to be effective [40, 41] or yield an antibody response [42] in individuals with high CD4 T-cell counts and may be detrimental in some settings [16] .
Our study has both strengths and limitations. To our knowledge, it is the largest study of protein-and serotype-specific responses to IPD. However, a larger sample size would increase the statistical power. Only individuals who survived their acute episode of IPD were included, thereby possibly introducing a selection bias (eg, if specific serotypes are associated with an increased risk of short-term mortality for HIV-infected individuals, as is the case for non-HIV IPD) [43] . We determined the levels of 30 different serotype-specific antibodies and protein antibodies against 27 proteins, but did not measure opsonophagocytic activity. Plasma HIV RNA levels were unavailable for most subjects and, thus, were not included in the analysis. A recent Canadian study [44] showed that HIV viremia was a predictor of a poor response to vaccination with PPV23. Similarly, antibody responses following natural infection may be diminished in viremic individuals. Several reports have questioned PPV23's effectiveness in reducing pneumococcal disease among non-ART HIV-infected individuals [16, 17] , and PCV are advantageous to PPV23 in HIV both ART-negative and -positive patients [45] . Cases and controls were matched on sex and age. Unfortunately, there remained an imbalance with regard to ART and immunosuppression (CD4 T-cell count), so controls were more likely to be treated with ART and had higher CD4 T-cell counts. Finally, we did not have a control group of HIV-uninfected individuals with pre-and post-IPD samples available for comparison.
In conclusion, we show that an antibody response occurred more frequently to pneumococcal proteins than to polysaccharide. Further, protein antibodies persisted for longer than polysaccharide-specific antibodies. HIV-related factors, such as CD4 T-cell count and ART, did not influence the protein-specific or serotype-specific antibody response in this population.
The most immunogenic proteins following natural infection were PiaA, PsaA, and PcpA within the ABC transporter and choline-binding proteins groups.
